Drug Profile
Khellin
Alternative Names: Khelline; Khellinum; KUVA; VisamminLatest Information Update: 09 Nov 2006
Price :
$50
*
At a glance
- Originator Ardeypharm; Loges; Nonindustrial source
- Class Antiasthmatics; Bronchodilators; Ischaemic heart disorder therapies; Psoralens; Small molecules; Vasodilators
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Marketed Cardiovascular disorders
- Discontinued Alopecia; Vitiligo
Most Recent Events
- 05 Dec 2003 No development reported - Clinical-Phase-Unknown for Vitiligo in Bulgaria (Topical)
- 05 Dec 2003 No development reported - Clinical-Phase-Unknown for Vitiligo in South Africa (Topical)
- 22 Sep 2000 No-Development-Reported for Alopecia in Italy (Topical)